TERUMO CORP

Terumo’s stock price has surged due to Japan’s economic resurgence, but its long-term success will depend on its financial performance and the healthcare sector’s trends.

Terumo’s stock price has surged to a 52-week high, reflecting the company’s strong performance and impressive sales of its SOFIA 88 Catheter.

Terumo Corporation’s stock price has experienced a moderate decline, but the company’s strong market position and the promising outlook for the health care equipment and supply sector suggest a potential rebound.

Terumo Corporation has partnered with MedHub-AI to bring AI-based coronary physiology assessment technology to the Japanese market, marking a significant milestone in the industry.

Terumo Corporation has partnered with MedHub-AI to market AI-based FFR technology in Japan, aiming to improve coronary physiology assessment and drive growth in the patient temperature monitoring market.

Terumo Corporation’s Q4 2025 earnings exceeded expectations, with a 25% revenue growth, 30% increase in earnings per share, and a 15% rise in stock price, solidifying its position as a leader in the healthcare equipment industry.

Terumo Corporation has received FDA clearances for its Medis QFR 3.0 software and Carotid Stent System, marking notable achievements for the company’s divisions, Terumo Health Outcomes and Terumo Neuro.

Terumo’s WEB device celebrates 15 years of revolutionizing aneurysm treatment, but its stock price suggests a company struggling to find its footing.

The global interventional neuroradiology market is expected to experience significant growth due to increasing prevalence of neurological disorders and demand for minimally invasive treatments.

Terumo has reported strong financial results, but its cardiovascular division is facing concerns over allegations of monopolizing medical equipment repair.